An interventional study of Edwards EWJ-202 Transcatheter Tricuspid Valve Replacement System in Tricuspid Valve Regurgitation, Heart Valve Diseases and Cardiovascular Diseases, sponsored by Edwards Lifesciences. Active, not recruiting at 8 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by Edwards Lifesciences · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Tricuspid Valve Insufficiency by Edwards Lifesciences — 3 open to participants now, 10 under way, none of them phase 3. Tricuspid Valve Insufficiency · Edwards Lifesciences.
Among the 14 studies in Tricuspid Valve Insufficiency by Edwards Lifesciences, this one is the only one that started in 2023, is one of 9 with no phase, and was the 11th registered.
229 studies on the registry are indexed under Tricuspid Valve Insufficiency; 111 are open to participants now.
Browse Tricuspid Valve Insufficiency studies →3 of the 14 studies in Tricuspid Valve Insufficiency by Edwards Lifesciences are open now, in 7 countries. Recruiting first, the newest first:
Edwards Lifesciences · Sites in United States
Ages 65+
Edwards Lifesciences · Sites in Germany, Greece, Italy and 3 more countries
Edwards Lifesciences · Sites in United States
Ages 65+
By country, each count listing its studies:
Of the 81 Tricuspid Valve Insufficiency studies recruiting now, 67 (83%) set no upper age limit and none (0%) stop at 75 or younger; 7 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 1 started in 2023.
This study's enrollment of 53 is below the median of 60 across 129 interventional studies indexed under Tricuspid Valve Insufficiency.
Median enrollment 65 across the 9 interventional studies, 500 across the 5 observational. Of the 4 that completed or were terminated, 4 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
Edwards Lifesciences is the lead sponsor of 128 studies on the registry; 17 are open to participants now.
Of its 35 completed or terminated interventional studies of FDA-regulated products, 33 (94%) have results posted.
1 of the studies in Tricuspid Valve Insufficiency by Edwards Lifesciences that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03382457Edwards LifesciencesClinical Study of Edwards Cardioband FIT Valve Repair System | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 14 studies in Tricuspid Valve Insufficiency by Edwards Lifesciences, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A prospective, open, non-randomized, multicenter, clinical trial to evaluate the safety and effectiveness of the Edwards EWJ-202 transcatheter tricuspid valve replacement system in the treatment of patients with at least severe tricuspid regurgitation despite medical therapy. Subjects will be followed at discharge, 30 days, 6 months and annually through 5 years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Edwards EWJ-202 Transcatheter Tricuspid Valve Replacement System
Replacement of the native tricuspid valve through a transcatheter approach
All-Cause Mortality
Co-primary Endpoint: All-cause mortality through 1 year, estimated using the Kaplan-Meier method.
Time frame: 1 year
Heart Failure Hospitalization
Co-primary Endpoint: Heart failure hospitalization through 1 year, estimated using the Kaplan-Meier method.
Time frame: 1 Year
Composite Major Adverse Event (MAE) Rate Through 30 Days
Composite MAE rate through 30 days, including cardiovascular mortality, myocardial infarction, stroke, new need for renal therapy, severe bleeding, non-elective tricuspid valve re-intervention (percutaneous or surgical), major access site and vascular complications, major cardiac structural complications due to access-related issues, device-related pulmonary embolism, arrhythmia and conduction disorder requiring permanent pacing.
Time frame: 30 Days
\[Not Specified\]
| Milestone | Edwards EVOQUE Tricuspid Valve Replacement System |
|---|---|
| Started | 53 |
| Completed | 53 |
| Not completed | 0 |
| Milestone | Edwards EVOQUE Tricuspid Valve Replacement System |
|---|---|
| Started | 53 |
| Completed | 48 |
| Not completed | 5 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Death | 4 |
Co-primary Endpoint: All-cause mortality through 1 year, estimated using the Kaplan-Meier method.
| Percentage of Participants | Edwards EVOQUE Tricuspid Valve Replacement System |
|---|---|
| All-Cause Mortality | 7.7 (3.0 to 19.2) |
Co-primary Endpoint: Heart failure hospitalization through 1 year, estimated using the Kaplan-Meier method.
| Percentage of Participants | Edwards EVOQUE Tricuspid Valve Replacement System |
|---|---|
| Heart Failure Hospitalization | 7.6 (2.9 to 19.1) |
Composite MAE rate through 30 days, including cardiovascular mortality, myocardial infarction, stroke, new need for renal therapy, severe bleeding, non-elective tricuspid valve re-intervention (percutaneous or surgical), major access site and vascular complications, major cardiac structural complications due to access-related issues, device-related pulmonary embolism, arrhythmia and conduction disorder requiring permanent pacing.
| Participants | Edwards EVOQUE Tricuspid Valve Replacement System |
|---|---|
| Composite Major Adverse Event (MAE) Rate Through 30 Days | 12 |
Collected over All-cause mortality was assessed through the 1-year follow-up period (Day 410). Serious adverse events and other (not including serious) adverse events were assessed through Day 365.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Edwards EVOQUE Tricuspid Valve Replacement System | 4/53 (7.5%) | 29/53 (54.7%) | 18/53 (34%) |
| Event | Edwards EVOQUE Tricuspid Valve Replacement System |
|---|---|
| Atrioventricular block completeCardiac disorders | 7/53 |
| Cardiac failureCardiac disorders | 6/53 |
| Prosthetic cardiac valve thrombosisGeneral disorders | 3/53 |
| PyrexiaGeneral disorders | 3/53 |
| COVID-19Infections and infestations | 3/53 |
| AnaemiaBlood and lymphatic system disorders | 2/53 |
| Atrial fibrillationCardiac disorders | 2/53 |
| Lower gastrointestinal haemorrhageGastrointestinal disorders | 2/53 |
| Cardiac failure chronicCardiac disorders | 1/53 |
| Mitral valve incompetenceCardiac disorders | 1/53 |
| Event | Edwards EVOQUE Tricuspid Valve Replacement System |
|---|---|
| Bundle branch block rightCardiac disorders | 6/53 |
| Cardiac failureCardiac disorders | 4/53 |
| ContusionInjury, poisoning and procedural complications | 4/53 |
| AnaemiaBlood and lymphatic system disorders | 3/53 |
| Compression fractureInjury, poisoning and procedural complications | 3/53 |
| Head injuryInjury, poisoning and procedural complications | 3/53 |
| Age, Continuous(Years) | Edwards EVOQUE Tricuspid Valve Replacement System |
|---|---|
| Mean | 82.6 ± 5.11 |
| Sex: Female, Male(Participants) | Edwards EVOQUE Tricuspid Valve Replacement System |
|---|---|
| Female | 26 |
| Male | 27 |
| Race and Ethnicity Not Collected(Participants) | Edwards EVOQUE Tricuspid Valve Replacement System |
|---|
| Cardiac Valve Disease (stenosis or regurgitation, excluding tricuspid)(Participants) | Edwards EVOQUE Tricuspid Valve Replacement System |
|---|---|
| Aortic | 2 |
| Mitral | 4 |
| Pulmonic | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2023 to primary completion in Aug 2025, 30 months.
Results were first posted in Oct 2026, 1 year 2 months after primary completion.
Of 55 industry-sponsored interventional studies with no phase under Tricuspid Valve Insufficiency, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 70. This study's 30 months is below that.
Counting every sponsor, half of 86 studies reached it within 38 months; a quarter within 23 and three quarters within 58.
Primary completion moved once since we started tracking on Sep 25, 2026: Sep 2025 → Aug 2025, on Oct 27, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tricuspid Valve Insufficiency →